GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medirom Healthcare Technologies MRM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.28

+0.64%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$4.0m

FY2018FY2025

Net income

$374,720

FY2018FY2025

Free cash flow

—

FY2018FY2025

Shareholders' equity

$1.33bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$4.0m$8.30bn$6.83bn$6.95bn$5.41bn$3.34bn$3.91bn$3.43bn
Research and development—————$13.5m——
Operating income$414,306$97.5m$57.5m$97.0m−$403.4m−$746.1m$34.4m$88.0m
Net income$374,720$148.8m$115.0m$149.0m−$990.7m−$539.2m$17.3m$66.3m
Diluted earnings per share0.0518.8323.5630.51-202.91-111.804.0614.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$4.16bn$8.09bn$6.85bn$6.75bn$5.75bn$5.71bn$4.76bn$4.52bn
Cash and short-term investments$20.1m$335.6m$132.8m$606.0m$397.1m$1.47bn$552.1m$244.7m
Total liabilities$2.82bn$6.90bn$6.63bn$6.81bn$5.96bn$5.22bn$4.16bn$4.64bn
Debt$1.74bn$2.67bn$2.31bn$2.02bn$1.66bn$1.57bn$1.23bn$1.52bn
Shareholders' equity$1.33bn$933.3m$210.9m−$59.4m−$208.3m$491.3m$600.1m−$117.6m
Shares outstanding8m8m5m5m5m5m4m5m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations—−$1.33bn−$631.7m−$685.7m−$557.2m−$366.4m$7.9m$141.9m
Capital spending—−$564.8m−$135.8m−$120.7m−$113.8m−$73.6m−$7.4m−$34.3m
Free cash flow—−$1.90bn−$767.6m−$806.4m−$671.0m−$440.0m$464,000$107.6m

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Mar 2025Sept 2024Jun 2024Mar 2024Sept 2023
Revenue$612.0m$612.0m$3.15bn$4.82bn$3.48bn$3.48bn$3.59bn$3.24bn
Operating income$70.6m$70.6m−$814.6m$618.6m−$636.7m−$636.7m−$81.3m−$310.3m
Net income$63.4m$63.4m−$671.1m$730.9m−$582.2m−$582.2m$470.5m−$355.1m
Diluted earnings per share8.028.02-84.8992.47-73.68-73.6859.54-72.72
Cash from operations——−$342.0m−$545.0m−$831.0m−$785.0m$27.0m−$610.0m
Capital spending——−$16.0m−$546.0m−$18.0m−$18.0m−$79.0m−$56.0m
Free cash flow——−$358.0m−$1.09bn−$849.0m−$803.0m−$52.0m−$666.0m
Total assets$4.16bn$4.16bn$7.98bn$8.09bn$5.83bn$5.83bn$6.85bn$6.06bn
Cash and short-term investments$20.1m$20.1m$38.8m$335.6m$144.6m$144.6m$106.8m$117.7m
Debt$1.74bn$1.74bn$2.04bn$1.91bn$1.33bn$2.35bn$1.26bn$839.3m
Shareholders' equity$1.33bn$1.33bn$442.3m$933.3m−$363.2m−$363.2m$210.9m−$414.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-91.7%-73.9%—
Operating income-83.8%——
Net income-86.4%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin1.2%1.1%-2.9%—
Net margin1.8%1.9%-3.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings25.10.00.10.1-0.0-0.1
Price to sales2.3————0.0

Share price return

Finished calendar years

20252024202320222021
Return117%-55%-38%-11%-56%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.